Glycylcyclines: Difference between revisions
| Line 27: | Line 27: | ||
=== References === | === References === | ||
* {{Cite | * {{Cite | ||
| | | author = článek | ||
| surname1 = Vojtová | | surname1 = Vojtová | ||
| name1 = Vladimíra | | name1 = Vladimíra | ||
Revision as of 20:30, 26 January 2023
Glycylcyclines represent a new group of antibiotics that is derived from the tetracycline antibiotic minocycline. The main representative is tigecycline'. Tigecycline is a broad-spectrum ATB (effective against Gram-negative, Gram-positive and anaerobic microbes, but not effective against pseudomonads and proteums). Tigecycline is chemically a ``9-t-butylglycylamido derivative of minocycline.
Indication
They are indicated for complicated skin and soft tissue infections as well as intra-abdominal infections.
Mechanism of action
Their mechanism of action is: inhibition of proteosynthesis, (blocking of translation of protein in bacteria by binding to the ribosomal subunit 30S', blocks the entry of aminoacyl-tRNA molecules into the A site of the ribosome ).
Antimicrobial spectrum
It is a broad-spectrum antibiotic' that acts on many clinically important bacteria. Both gram-positive, gram-negative, anaerobic and atypical, including some multi-resistant, penicillin resistant Streptococcus pneumoniae, Klebsiella pneumoniae and Escherichia coli , Staphylococcus aureus, from gram-negative bacteria shows a lower sensitivity to Pseudomonas aeruginosa, Proteus mirabilis, Burkholderia cepacia and Stenotrophomonas malthophilia.
Side effects
Side effects are:
